We have shown that superparamagnetic iron oxide (Fe3O4) nanoparticles with a surface functionalization of dimercaptosuccinic acid (DMSA) are an effective sorbent material for toxic soft metals such as Hg, Ag, Pb, Cd, and Tl, which effectively bind to the DMSA ligands and for As, which binds to the iron oxide lattices. The nanoparticles are highly dispersible and stable in solutions, have a large surface area (114 m2/g), and have a high functional group content (1.8 mmol thiols/g). They are attracted to a magnetic field and can be separated from solution within a minute with a 1.2 T magnet. The chemical affinity, capacity, kinetics, and stability of the magnetic nanoparticles were compared to those of conventional resin based sorbents (GT-73), activated carbon, and nanoporous silica (SAMMS) of similar surface chemistries in river water, groundwater, seawater, and human blood and plasma. DMSA-Fe3O4 had a capacity of 227 mg of Hg/g, a 30-fold larger value than GT-73. The nanoparticles removed 99 wt% of 1 mg/L Pb within a minute, while it took over 10 and 120 min for Chelex-100 and GT-73 to remove 96% of Pb.

In vivo delivery of siRNAs designed to inhibit genes important in cancer and other diseases continues to be an important biomedical goal. We now describe a new nanoparticle construct that has been engineered for efficient delivery of siRNA to tumors. The construct is comprised of a 47-nm mesoporous silica nanoparticle (MSNP) core coated with a cross-linked PEI-PEG copolymer, carrying siRNA against the HER2 oncogene, and coupled to the anti-HER2 monoclonal antibody (trastuzumab). The construct has been engineered to increase siRNA blood half-life, enhance tumor-specific cellular uptake, and maximize siRNA knockdown efficacy. The optimized anti-HER2-nanoparticles produced apoptotic death in HER2 positive (HER2+) breast cancer cells grown in vitro, but not in HER2 negative (HER2−) cells. One dose of the siHER2-nanoparticles reduced HER2 protein levels by 60% in trastuzumab-resistant HCC1954 xenografts. Multiple doses administered intravenously over 3 weeks significantly inhibited tumor growth (p < 0.004). The siHER2-nanoparticles have an excellent safety profile in terms of blood compatibility and low cytokine induction, when exposed to human peripheral blood mononuclear cells. The construct can be produced with high batch-to-batch reproducibility and the production methods are suitable for large-scale production. These results suggest that this siHER2-nanoparticle is ready for clinical evaluation.

Copper(II) ferrocyanide on mesoporous silica (FC-Cu-EDA-SAMMS™) has been evaluated against iron(III) hexacyanoferrate(II) (insoluble Prussian Blue) for removing cesium (Cs+) and thallium (Tl+) from natural waters and simulated acidic and alkaline wastes. From pH 0.1 – 7.3, FC-Cu-EDA-SAMMS had greater affinities for Cs and Tl and was less affected by the solution pH, competing cations, and matrices. SAMMS also outperformed Prussian Blue in terms of adsorption capacities (e.g., 21.7 versus 2.6 mg Cs/g in acidic waste stimulant (pH 1.1), 28.3 versus 5.8 mg Tl/g in seawater), and rate (e.g., over 95 wt% of Cs was removed from seawater after 2 min with SAMMS, while only 75 wt% was removed with Prussian Blue). SAMMS also had higher stability (e.g., 2.5 to 13-fold less Fe dissolved from 2 to 24 hr of contact time). In addition to environmental applications, SAMMS has great potential to be used as orally administered drug for limiting the absorption of radioactive Cs and toxic Tl in gastrointestinal tract.